Stoke Therapeutics Quarterly Balance Sheet
NASDAQ: STOKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Stoke Therapeutics financial position
As of Jun 30, 2026, Stoke Therapeutics reported total assets of $394.0 million, up 2.5% from a year earlier against total liabilities of $48.4 million. Shareholders' equity stood at $345.5 million, or 87.7% of assets. The company held $110.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 7.69, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Stoke Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 110.00M | 155.66M | 84.22M | 83.39M | 101.47M | 274.82M | 127.98M | 150.02M | 193.48M | 178.58M | 191.44M | 189.98M |
| Short-Term Investments | 182.81M | 187.89M | 200.45M | 164.92M | 146.24M | 82.51M | 88.92M | 89.18M | 88.51M | — | 9.95M | 24.74M |
| Receivables | 7.18M | 4.45M | 5.94M | 9.25M | — | — | 1.67M | — | — | — | — | — |
| Total Current Assets | 322.54M | 366.68M | 305.70M | 272.44M | 269.97M | 375.74M | 232.76M | 253.61M | 296.99M | 193.28M | 215.34M | 230.02M |
| Property, Plant & Equipment | 4.83M | 3.40M | 3.15M | 3.08M | 3.34M | 3.61M | 3.91M | 4.33M | 4.77M | 5.28M | 5.82M | 6.22M |
| Long-Term Investments | 61.50M | 67.48M | 106.26M | 80.31M | 107.26M | 22.99M | 29.82M | 29.95M | — | — | — | — |
| Total Assets | 393.97M | 443.28M | 418.43M | 360.26M | 384.51M | 406.89M | 271.56M | 293.32M | 307.76M | 205.18M | 228.34M | 239.89M |
| Accounts Payable | 4.79M | 6.84M | 4.94M | 5.87M | 4.31M | 2.19M | 2.50M | 2.48M | 3.94M | 2.10M | 1.70M | 3.08M |
| Total Current Liabilities | 41.93M | 40.81M | 57.88M | 41.73M | 38.68M | 44.69M | 40.06M | 49.87M | 44.50M | 35.59M | 30.82M | 25.20M |
| Total Liabilities | 48.42M | 48.40M | 65.98M | 52.16M | 49.56M | 56.81M | 42.53M | 61.21M | 65.05M | 64.84M | 68.78M | 66.89M |
| Shareholders' Equity | 345.55M | 394.88M | 352.46M | 308.11M | 334.94M | 350.07M | 229.02M | 232.11M | 242.71M | 140.34M | 159.56M | 173.00M |
| Retained Earnings | -609.34M | -547.72M | -497.71M | -439.78M | -401.43M | -377.95M | -490.83M | -480.35M | -453.92M | -428.22M | -401.85M | -374.89M |
| Net Cash (Debt) | 292.82M | 343.55M | 284.67M | 248.31M | 247.71M | 357.32M | 216.90M | 239.20M | 281.98M | 178.58M | 201.39M | 214.72M |
| Shares Outstanding | 62.40M | 62.24M | 58.92M | 55.12M | 54.72M | 54.60M | 54.03M | 52.94M | 52.31M | 46.50M | 45.92M | 44.29M |
This table shows 12 quarterly periods of Stoke Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow STOK's reporting calendar. What is a balance sheet?